Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH), classed as a GnRH superagonist because a single amino acid substitution gives it substantially greater receptor affinity and metabolic stability than the native hormone. It is studied for its distinctive two-phase action on the pituitary-gonadal axis: an initial stimulation of gonadotropin and sex-steroid secretion, followed by sustained suppression with continued exposure, a property that has made it a widely used tool in reproductive endocrinology and hormone-dependent tumour research. This article reviews triptorelin’s structure, receptor mechanism, key published studies, research applications and the handling requirements relevant to a laboratory setting.
What is triptorelin?
Triptorelin is a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂, differing from native gonadorelin (GnRH) at a single position, where the natural glycine at position 6 is replaced by a D-tryptophan residue. This single substitution is reported to protect the peptide from enzymatic cleavage at that site, substantially extending its biological half-life relative to the native decapeptide, and also increases its binding affinity for the GnRH receptor. Its molecular weight is approximately 1,311 g/mol as the free peptide; research-grade and clinical material is commonly supplied as the acetate or pamoate salt, which affects the mass reported on a certificate of analysis without altering the peptide’s own sequence.
Triptorelin was developed in the late 1970s as part of a wider research programme into D-amino-acid-substituted GnRH analogues, led by Andrew Schally’s group alongside collaborators including David Coy and Jesus Vilchez-Martinez, building directly on the same laboratory’s earlier isolation and structural characterisation of native GnRH. Early pharmacological characterisation of D-Trp6-substituted GnRH analogues, including studies in immature female rats, described the compound’s unusual stimulatory-then-suppressive profile, distinguishing it from the simple stimulatory action of the native hormone (Vilchez-Martinez et al., 1979, PubMed).
Mechanism of action
Triptorelin acts on the same receptor as native GnRH, the Gq/11-coupled GnRH receptor (GnRHR) expressed on pituitary gonadotrophs, but its prolonged receptor occupancy produces a markedly different physiological time course. Initial exposure produces the same acute signalling cascade as native GnRH: phospholipase C activation, generation of inositol trisphosphate and diacylglycerol, calcium mobilisation and consequent release of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives a transient rise in gonadal sex-steroid output. This initial phase is sometimes referred to in the literature as a “flare” response.
With continued, non-pulsatile exposure, however, the sustained receptor occupancy that makes triptorelin so potent also drives homologous desensitization and down-regulation of the GnRH receptor on gonadotrophs, the same general mechanism described for continuous native GnRH exposure but achieved more efficiently because of the analogue’s resistance to degradation. The result, after an initial stimulatory period lasting one to three weeks in most reported animal and clinical pharmacology studies, is a sustained suppression of LH and FSH secretion and, consequently, of gonadal steroidogenesis, a state functionally equivalent to surgical gonadectomy and often described as medical or chemical castration in the literature.
Because this suppression depends on continuous rather than pulsatile receptor occupancy, triptorelin’s pharmacological profile is the practical inverse of the pulsatile dosing regimens used experimentally with native gonadorelin to sustain pituitary responsiveness. This dual-phase mechanism, stimulation followed by suppression, is the central feature that distinguishes GnRH superagonists as a pharmacological class and is the basis for most of the research applications described below.
What the research shows
The initial-phase stimulation followed by sustained suppression was characterised directly in non-human primates by Sundaram and colleagues, who reported in Endocrinology in 1982 a study in male rhesus monkeys. Acute administration of triptorelin produced dose-related increases in serum testosterone and bioassayable LH. However, twice-weekly administration over twelve weeks produced a 75% decrease in the LH response to successive doses, and daily administration over a subsequent sixteen-week period reduced or abolished the testosterone response in the treated animals, while sperm motility and count, assessed by electroejaculation, were not affected during the twice-weekly regimen (Sundaram et al., 1982, PubMed).
The compound’s effects on hormone-dependent tumour growth were examined by de la Cruz and colleagues, who reported in the Proceedings of the National Academy of Sciences in 1985 a study using the Dunning R-3327H rat model of androgen-dependent prostate cancer. The investigators tested long-acting, controlled-release microcapsule formulations of triptorelin, alone and combined with the chemotherapeutic agent cyclophosphamide, and reported that treatment suppressed serum testosterone to undetectable levels, reduced testicular and prostate weight, and reduced prolactin, in both treatment arms (de la Cruz et al., 1985, PMC).
More recent work has continued to use triptorelin in rat models of reproductive physiology. A 2025 study published in the International Journal of Molecular Sciences examined testicular histology and function in juvenile rats following triptorelin administration, reporting that treated animals showed significantly lower plasma testosterone than controls at defined developmental timepoints, alongside focal and partial testicular atrophy on histological examination that was reported to be reversible and did not eliminate sperm production in the model studied (2025, PMC). This recent publication illustrates that triptorelin’s reproductive-axis pharmacology in rodent models remains an active area of investigation, extending the receptor and endocrine findings established in the earlier primate and tumour-model studies above.
A substantial additional body of rodent work, spanning several research groups from the early 1980s onward, has examined whether GnRH superagonists such as triptorelin act solely by suppressing pituitary gonadotropin secretion or also exert direct effects on gonadal steroidogenic enzymes, with some studies reporting a direct inhibitory action on testicular testosterone biosynthesis independent of the pituitary. Because this literature is extensive, readers wanting further primary detail on direct gonadal mechanisms should consult a review of GnRH agonist pharmacology rather than a single summarised study here.
Research applications
In the laboratory, triptorelin is used chiefly as a pharmacological tool for inducing reversible, reproducible suppression of the hypothalamic-pituitary-gonadal axis in animal models, exploiting the sustained receptor desensitization described above. This makes it a standard agent in rodent and primate studies requiring a hypogonadal or androgen-deprived state, including studies of hormone-dependent tissue growth, reproductive physiology and the role of sex steroids in processes unrelated to reproduction, such as some bone and metabolic research.
Hormone-dependent tumour models are a major application, drawing directly on the kind of androgen-dependent rat prostate cancer work described above; triptorelin and related GnRH superagonists are used as reference tools for inducing androgen deprivation in such models, including in combination with chemotherapeutic agents to study combined treatment effects on tumour growth.
In vitro receptor pharmacology, using pituitary cell culture or cell lines engineered to express the GnRH receptor, is used to characterise triptorelin’s binding affinity and signalling kinetics relative to native gonadorelin and to other GnRH agonist and antagonist analogues, exploiting the same receptor desensitization assays developed originally for native GnRH. Controlled-release and long-acting formulation research, including the microcapsule and depot delivery systems referenced in the tumour-model study above, also uses triptorelin as a reference peptide for studying sustained-release pharmacokinetics.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Triptorelin should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those comparing suppliers should look for the same documentation from any best peptides supplier UK they consider.
Reversed-phase HPLC separates the intact decapeptide from truncated or deletion sequences and residual synthesis by-products, and research-grade material is commonly specified at 98% purity or above. Mass spectrometry alongside HPLC confirms identity against the expected mass of approximately 1,311 daltons for the free peptide, with the observed mass differing where the material is supplied as an acetate or pamoate salt; a batch-specific certificate of analysis should report both the peptide purity and the salt form separately, since this affects the active peptide content calculated from a given mass of powder.
Lyophilised triptorelin should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once reconstituted in sterile water or an appropriate buffer, the peptide should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles risk degrading the peptide. The tryptophan residues within the sequence, including the D-tryptophan substitution that defines the analogue, are particularly susceptible to photo-oxidation, so amber vials or foil-wrapped storage are sensible precautions during handling. Published reconstituted-stability data specific to research-grade triptorelin are limited in the open literature, so laboratories should validate their own working window empirically, for example by re-running HPLC on aliquots at defined time points.
Frequently asked questions
What is triptorelin used for in research?
It is used mainly as a pharmacological tool for inducing reversible suppression of the hypothalamic-pituitary-gonadal axis in animal models, in hormone-dependent tumour research, and in studies of GnRH receptor signalling and desensitization. It is not evaluated here as a treatment, and this article makes no claims about use in humans.
How does triptorelin differ from native GnRH (gonadorelin)?
Triptorelin differs from native gonadorelin at a single position, where a D-tryptophan residue replaces the natural glycine at position 6, which increases both receptor binding affinity and resistance to enzymatic degradation. This gives triptorelin a far longer duration of receptor occupancy than native GnRH, producing sustained receptor desensitization rather than the pulsatile stimulation pattern required to sustain pituitary responsiveness with the native hormone.
Why does triptorelin stimulate hormone secretion initially before suppressing it?
Initial exposure activates the GnRH receptor in the same way as native GnRH, triggering an acute rise in LH, FSH and downstream sex-steroid secretion. Because triptorelin resists degradation, receptor occupancy persists well beyond a normal physiological pulse, and this sustained occupancy drives receptor down-regulation and desensitization, producing suppressed gonadotropin and sex-steroid secretion after an initial stimulatory period of one to several weeks in most published animal studies.
Is triptorelin an approved medicine?
Triptorelin is a licensed prescription medicine in the UK and elsewhere, marketed under names including Decapeptyl, for several hormone-dependent conditions in specialist clinical settings. This article concerns laboratory research material only, which is not equivalent to a licensed pharmaceutical product, and makes no claims about administration to humans or animals.
The triptorelin discussed in this article is supplied for in-vitro and in-vivo laboratory research only. It is not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
